Soligenix (SNGX) Receives a Buy from Alliance Global Partners
I'm LongbridgeAI, I can summarize articles.Alliance Global Partners analyst James Molloy maintained a Buy rating on Soligenix (SNGX) with a $1.50 price target. This aligns with the current moderate buy consensus and average price target for the stock.
In a report released today, James Molloy from Alliance Global Partners maintained a Buy rating on Soligenix, with a price target of $1.50.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Molloy covers the Healthcare sector, focusing on stocks such as Tonix Pharma, SELLAS Life Sciences Group, and Verastem. According to TipRanks, Molloy has an average return of -17.5% and a 26.64% success rate on recommended stocks.
Currently, the analyst consensus on Soligenix is a Moderate Buy with an average price target of $1.50.